Please login to the form below

Not currently logged in
Email:
Password:

Replagal

This page shows the latest Replagal news and features for those working in and with pharma, biotech and healthcare.

Amicus gets NICE green light for Fabry drug

Amicus gets NICE green light for Fabry drug

Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal

Latest news

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics